Related Experiment Video

Updated: Oct 14, 2025

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

69.7K

A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors

Pallavi Prakash Chaurasia1, Sagar Dholariya2, Fenilkumar Kotadiya3

  • 1Internal Medicine, RotaCare Clinic, Walnut Creek, USA.

Cureus
|November 1, 2021
PubMed

Insights

Sodium-glucose cotransporter inhibitors (SGLTi) offer dual protection for diabetic patients, reducing cardiovascular and kidney disease risks. These SGLT2 inhibitors improve glycemic control and prevent long-term diabetes complications.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Diabetes mellitus leads to severe organ damage, including nephropathy, retinopathy, and cardiovascular events, primarily due to prolonged hyperglycemia.
  • Effective management requires treatments that delay complications and provide multi-organ protection.

Purpose of the Study:

  • To review clinical trial data on the efficacy of SGLT2 inhibitors in managing cardiovascular and renal outcomes in T2DM patients.
  • To highlight the nephroprotective and cardioprotective roles of SGLT2 inhibitors.

Main Methods:

  • Review of clinical trial data focusing on SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin).
  • Analysis of outcomes related to renal disease progression, heart failure hospitalization, and cardiovascular mortality.

Main Results:

  • SGLT2 inhibitors demonstrated significant reductions in heart failure hospitalizations, cardiovascular mortality, and diabetic kidney disease progression.
  • These agents improve glycemic control independently of insulin release, thus avoiding hypoglycemia.
  • Nephroprotective and cardioprotective benefits were observed, irrespective of diabetic status in some trials.

Conclusions:

  • SGLT2 inhibitors are effective in reducing cardiovascular and renal risks in patients with type 2 diabetes mellitus.
  • Their multi-organ protective effects make them a valuable therapeutic option for managing diabetes complications.
Keywords:
canagliflozincardiovascular diseaseclinical trialsdapagliflozindiabetic kidney diseaseempagliflozintype 2 diabetes mellitus

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

2.9K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
340
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
292
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
303
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
317
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
475